TY  - JOUR
AU  - Puig-Domingo, Manel
AU  - Bernabéu, Ignacio
AU  - Picó, Antonio
AU  - Biagetti, Betina
AU  - Gil, Joan
AU  - Alvarez-Escolá, Cristina
AU  - Jordà, Mireia
AU  - Marques-Pamies, Montserrat
AU  - Soldevila, Berta
AU  - Gálvez, María-Angeles
AU  - Cámara, Rosa
AU  - Aller, Javier
AU  - Lamas, Cristina
AU  - Marazuela, Mónica
PY  - 2021
DO  - 10.3389/fendo.2021.648411
SN  - 1664-2392
UR  - http://hdl.handle.net/10668/17441
T2  - Frontiers in endocrinology
AB  - The delay in controlling the disease in patients who do not respond to first-line treatment with first generation somatostatin receptor ligands (first-generation SRLs) can be quantified in years, as every modification in the medical therapy requires...
LA  - en
KW  - PitNETs
KW  - endocrine tumors
KW  - growth hormone
KW  - personalized medicine
KW  - resistance to medical treatment in acromegaly
KW  - somatostatin analogues
KW  - somatostatin receptor ligands
KW  - somatotroph adenoma
KW  - Acromegaly
KW  - Adenoma
KW  - Algorithms
KW  - Biomarkers
KW  - Endocrine Gland Neoplasms
KW  - Genetic Markers
KW  - Growth Hormone-Secreting Pituitary Adenoma
KW  - Humans
KW  - Image Processing, Computer-Assisted
KW  - Insulin-Like Growth Factor I
KW  - Ligands
KW  - Machine Learning
KW  - Magnetic Resonance Imaging
KW  - Models, Genetic
KW  - Octreotide
KW  - Phosphorylation
KW  - Precision Medicine
KW  - Receptors, Somatostatin
KW  - Somatostatin
KW  - Treatment Outcome
TI  - Pasireotide in the Personalized Treatment of Acromegaly.
TY  - research article
VL  - 12
ER  -